Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal for ImmunoTherapy of Cancer

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1136/jitc-2020-000891

License

CC-BY-NC

Other Formats

PDF